SecBot SecBot

MAIA

MAIA Biotechnology, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001878313 Biotech & Drug Discovery
$1.11 −0.04 (−3.48%)
Oct 26 4:00 PM ET · prev $1.15
Market cap
$69.8M
Micro cap
Median target
$12.00
+981% · range $10.00–14.00
Next earnings
Nov 5
in 9 days · EPS est. −$0.13
1 year
−26.0%
from $1.50 · Oct 27
30 days
−5.9%
from $1.18
52-week range
$0.8710–2.95
−62% from high · low Nov 20
Avg volume 20D
406.1K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$556.1K
4 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 2 bearish · 3 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 5/6 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH MAIA Biotechnology dosed the first U.S. patient in the Phase 2 THIO-101 trial expansion for ateganosine in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $556.1K at an average $1.36. No open-market sales. Price is 19% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 7 added (0 new), 1 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.120 → −$0.130 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    12% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCADD504,380$726.6K
BlackRock, Inc.DOUBLED403,011$580.3K
VANGUARD FIDUCIARY TRUST COADD336,688$484.8K
STATE STREET CORPADD201,750$290.5K
NORTHERN TRUST CORPDOUBLED125,171$180.2K
MORGAN STANLEYDOUBLED104,017$149.8K
UBS Group AGTRIM33,435$48.1K
CITIGROUP INCDOUBLED150$216.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Feb 2023
12-month targets · 2 analysts

Price is below the lowest target. Median implies +981%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Feb 21, 2023Noble Capital Markets
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$556.1K
bought · 4 insiders
$0
sold · 0 insiders
−18.6%
vs their $1.36 cost
DateInsiderTypeValue
Sep 30, 2026
Guerrero Ramiro
Director
AWARD32,012 sh
Sep 30, 2026
Smith Stan
Director
AWARD38,871 sh
Sep 30, 2026
CHAOUKI STEVEN M
Director
AWARD32,774 sh
Sep 30, 2026
Louie Ngar Yee
Director
AWARD39,634 sh
Sep 30, 2026
Theagene Jean-Manasse
Director
AWARD32,012 sh
Sep 30, 2026
Luput Cristian
Director
AWARD33,536 sh
Sep 14, 2026
Vitoc Vlad
Chief Executive Officer
BUY$100.0K
Sep 10, 2026
Guerrero Ramiro
Director
BUY$49.5K

Earnings setup

Estimates
Nov 5
reports in 9 days
−$0.13
EPS estimate, this quarter
−8%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.13–-$0.13-8.3%$0.00
Next Q-$0.14-$0.14–-$0.14-7.7%$0.00
Current FY-$0.54-$0.54–-$0.54-3.8%$0.00
Next FY$1.11-$0.48–$2.70+0.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 7, 2026 SEC
The SEC declared effective MAIA Biotechnology's S-3 shelf registration (File No. 333-299148) on October 6, 2026. This…
EFFECT — Impact 5/10
Oct 6, 2026 SEC
MAIA Biotechnology filed an 8-K furnishing a corporate presentation and summary under Regulation FD, posted to its…
8-K — Impact 2/10
Sep 30, 2026 Insider
Guerrero Ramiro was granted 32,012 shares
Director
Sep 30, 2026 Insider
Smith Stan was granted 38,871 shares
Director
Sep 30, 2026 Insider
CHAOUKI STEVEN M was granted 32,774 shares
Director
Sep 30, 2026 Short interest report
Short Interest: MAIA up 28% to 2.7M shares
Settlement 2026-09-30 | Days to cover: 3.43 | ≈4.36% of shares outstanding (est.)
Sep 25, 2026 SEC
MAIA Biotechnology filed an S-3 registration statement to register 751,879 shares of common stock for resale by PoC…
S-3 — Impact 5/10
Sep 16, 2026 Press
MAIA Biotechnology dosed the first U.S. patient in the Phase 2 THIO-101 trial expansion for ateganosine in third-line…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
MAIA Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Sep 30, 2026
Short interest
Short Interest: MAIA up 28% to 2.7M shares
Settlement 2026-09-30 | Days to cover: 3.43 | ≈4.36% of shares outstanding (est.)
Sep 23, 2026
Press release
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
THIO-104 advances toward key 2027 interim survival analysis
Sep 22, 2026
Press release
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Strong pace of patient enrollment supports continued advancement toward regulatory milestones
Sep 16, 2026
FDA
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and…
Sep 15, 2026
M&A
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage…

SecBot reports

11 filings · 6 press releases · 4 bullish · 2 bearish · 1 mixed · 4 neutral
All MAIA filing & press-release reports (17)